Because Newton et al. (2000) only reported on reductions in prevalence associated with vaccination, and also because the model was fairly straight-forward to implement exactly as the authors had done, we reproduced their model in R using the deSolve package to solve the differential equations. The differential equations are:
Initial conditions are such that, from a total stable population size of 10000, 9500 are S, 1 is E, 2 are I H , 470 are I L , and 27 are I R . Under either vaccination scenario, the model is ran from its initial conditions for 20 years before vaccination begins.
Vaccine impact is calculated by comparing the incidence rate in each vaccination scenario to the incidence rate in the null scenario 10 years after vaccination began. Table 1 : Characteristics and predictions of HSV-2 vaccine modeling literature scenarios. Biological vaccine effects in parentheses reflect vaccines with some combination of susceptibility (S), infectiousness (I), and pathogenicity (P) effects. Multiple scenarios per article are possible when an article considered different scenarios defined by the type(s) of biological vaccine effects being conferred. Articles are organized by vaccine design (prophylactic, prophylactic with breakthrough effects, and therapeutic) and within these categories by increasing magnitude of impact. 1-sex models do not differentiate between males and females; 2-sex models represent females and males separately, allowing for vaccination of one or both sexes. Bounds represent upper and lower predictions either based on ranges from all the samples generated (Schwartz), or upper and lower estimates when only two data points were predicted (Garnett, Alsallaq, Freeman, Newton). * Vaccine increased duration of symptomatic period compared to unvaccinated
